A detailed history of Allianz Asset Management Gmb H transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Allianz Asset Management Gmb H holds 1,324,791 shares of HCM stock, worth $18.9 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,324,791
Previous 1,501,643 11.78%
Holding current value
$18.9 Million
Previous $25.7 Million 0.74%
% of portfolio
0.04%
Previous 0.04%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$16.03 - $20.31 $2.83 Million - $3.59 Million
-176,852 Reduced 11.78%
1,324,791 $25.9 Million
Q2 2024

Aug 13, 2024

SELL
$16.36 - $21.78 $1.04 Million - $1.39 Million
-63,715 Reduced 4.07%
1,501,643 $25.7 Million
Q1 2024

May 13, 2024

BUY
$12.08 - $18.56 $97,099 - $149,185
8,038 Added 0.52%
1,565,358 $26.3 Million
Q4 2023

Feb 12, 2024

SELL
$16.25 - $20.23 $1.42 Million - $1.77 Million
-87,679 Reduced 5.33%
1,557,320 $28.2 Million
Q3 2023

Nov 13, 2023

SELL
$11.85 - $16.95 $2.72 Million - $3.89 Million
-229,787 Reduced 12.26%
1,644,999 $27.9 Million
Q2 2023

Aug 11, 2023

SELL
$10.78 - $17.73 $2.99 Million - $4.91 Million
-277,151 Reduced 12.88%
1,874,786 $22.5 Million
Q1 2023

May 11, 2023

SELL
$13.02 - $19.87 $403,528 - $615,830
-30,993 Reduced 1.42%
2,151,937 $28 Million
Q4 2022

Feb 13, 2023

BUY
$7.65 - $15.51 $3.22 Million - $6.53 Million
421,241 Added 23.91%
2,182,930 $32.3 Million
Q3 2022

Nov 08, 2022

BUY
$8.63 - $15.52 $4.21 Million - $7.58 Million
488,185 Added 38.33%
1,761,689 $15.6 Million
Q2 2022

Aug 12, 2022

SELL
$8.59 - $20.77 $1.58 Million - $3.82 Million
-184,020 Reduced 12.63%
1,273,504 $16.1 Million
Q1 2022

May 13, 2022

SELL
$15.52 - $35.65 $1.91 Million - $4.39 Million
-123,014 Reduced 7.78%
1,457,524 $27.6 Million
Q4 2021

Feb 11, 2022

SELL
$28.89 - $35.33 $4.04 Million - $4.94 Million
-139,821 Reduced 8.13%
1,580,538 $55.4 Million
Q3 2021

Nov 10, 2021

SELL
$35.66 - $42.94 $7.49 Million - $9.03 Million
-210,178 Reduced 10.89%
1,720,359 $63 Million
Q2 2021

Aug 16, 2021

BUY
$23.7 - $39.27 $5.53 Million - $9.16 Million
233,239 Added 13.74%
1,930,537 $75.8 Million
Q1 2021

May 13, 2021

BUY
$27.01 - $36.8 $1.44 Million - $1.96 Million
53,216 Added 3.24%
1,697,298 $47.9 Million
Q4 2020

Feb 16, 2021

BUY
$27.51 - $34.36 $6.57 Million - $8.21 Million
238,840 Added 17.0%
1,644,082 $52.6 Million
Q3 2020

Nov 13, 2020

SELL
$25.8 - $34.61 $2.52 Million - $3.38 Million
-97,800 Reduced 6.51%
1,405,242 $45.4 Million
Q2 2020

Aug 14, 2020

BUY
$17.65 - $28.05 $3.97 Million - $6.32 Million
225,200 Added 17.62%
1,503,042 $41.5 Million
Q1 2020

May 14, 2020

BUY
$15.19 - $29.51 $8.29 Million - $16.1 Million
546,000 Added 74.61%
1,277,842 $22.8 Million
Q4 2019

Feb 13, 2020

SELL
$17.17 - $25.95 $182,585 - $275,952
-10,634 Reduced 1.43%
731,842 $18.3 Million
Q3 2019

Nov 13, 2019

BUY
$17.84 - $22.69 $1.21 Million - $1.53 Million
67,600 Added 10.02%
742,476 $13.2 Million
Q2 2019

Aug 08, 2019

BUY
$22.0 - $31.78 $1.58 Million - $2.28 Million
71,682 Added 11.88%
674,876 $14.8 Million
Q1 2019

May 13, 2019

BUY
$21.27 - $30.58 $3.31 Million - $4.76 Million
155,700 Added 34.79%
603,194 $18.4 Million
Q3 2018

Nov 13, 2018

BUY
$26.55 - $34.38 $3.82 Million - $4.94 Million
143,765 Added 47.33%
447,494 $14.4 Million
Q2 2018

Aug 13, 2018

BUY
$27.79 - $34.49 $1.83 Million - $2.27 Million
65,756 Added 27.63%
303,729 $9.15 Million
Q1 2018

May 14, 2018

BUY
$28.87 - $41.13 $1.81 Million - $2.58 Million
62,673 Added 35.75%
237,973 $7.03 Million
Q4 2017

Feb 13, 2018

SELL
$27.41 - $39.42 $3.4 Million - $4.88 Million
-123,900 Reduced 41.41%
175,300 $6.91 Million
Q3 2016

Apr 17, 2019

BUY
N/A
299,200
299,200 $3.56 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $2.47B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.